Use of combined oral contraceptives for the management of heavy menstrual bleeding

Luís Bahamondes, M. Valeria Bahamondes
In: Expert Review of Obstetrics & Gynecology · 2011 · vol. 6(5) , pp. 485–489 · doi:10.1586/eog.11.43 · W2093695518
article OA: closed CC0
View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

A randomized trial found that estradiol valerate and dienogest combined oral contraceptives significantly reduced heavy menstrual bleeding compared to placebo over six months.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Evaluation of: Jensen JT, Parke S, Mellinger U, Machlitt A, Fraser I. Effective treatment of heavy menstrual bleeding with estradiol valerate and dienogest: a randomized controlled trial. Obstet. Gynecol. 117(4), 777–787 (2011).Heavy menstrual bleeding (HMB) is one of the most common reasons for women to seek gynecological care. Surgical and medical treatments have been proposed, including hysterectomy, endometrial ablation, oral progestins, the levonorgestrel-releasing intrauterine system, mefenamic acid and combined oral contraceptives (COCs). Although COCs have been used extensively to control HMB, there is little evidence of their efficacy. A new COC containing estradiol valerate and dienogest was compared with placebo in a randomized clinical trial that included women with objectively confirmed HMB in whom blood loss was measured using the alkaline hematin method. Over 6 months of treatment, results showed that blood loss decreased significantly in COC users, both when compared with a placebo group and with a 90-day pretreatment period. This represents a new option for HMB treatment with the advantage of simultaneously providing contraception, a requirement for many women with HMB who wish to preserve their fertility. Despite these excellent results, the facts remain that HMB is a chronic medical condition and that this new therapy still requires long-term evaluation. Notwithstanding, this report is the first to describe the successful use of a COC to treat HMB, a challenging condition with limited options for conservative treatment.

My notes (saved in your browser only)

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (28)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
unpaywall
last seen: 2026-06-13T06:42:57.164913+00:00
License: CC0 · commercial use OK